FDA OKs New Option for Advanced ROS1-Positive Lung Cancer

(MedPage Today) -- The FDA approved repotrectinib (Augtyro) -- an oral tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions -- for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...

https://www.medpagetoday.com/hematologyoncology/lungcancer/107397

Source: MedPage Today Public Health - November 16, 2023 Category: American Health Source Type: news